Diagnostic Outcomes for Genetic Testing of 54 Genes in Pregnancy Loss Using Array CGH Method: A Two-Year Retrospective Study
Öz
Objective: The current study aimed to retrospectively evaluate different diag- nostic approaches for the array genetic analysis of the cases from all trimester fetal loss in the medical genetics clinic between 2016 and 2017. The Quantitati- ve Fluorescent Polymerase Chain Reaction(QFPCR) test was performed on 50 samples, and aneuploidy was detected in 11 samples as a result of the test, and the array-CGH was performed when 39 QF-PCR resulted in normal test results. Under this purpose, we aimed to analyze and determine the possible copy num- ber variation(CNV), gene deletions, and/or duplications involved in embryonic cell division, tissue differentiation, intended.
Materials and methods: DNA isolation from cases of this retrospective study was completed using the PureLink Genomic DNA isolation kit. DNA samples were then genoty - ped for molecular etiological reasons by oligonücleotid microarray -CGH method (aCGH , 60 K ISCA design , Agilent , Germany ). Hybridized probe correlations of the case and reference DNAs were evaluated with databases (Database of Genomic Variants Analysis ) used in genomic variation analysis in terms of 54 functional genes CNVs associated with intrauterine losses.
Results: CNV was detected in 30 (77%) of 39 fetal samples analyzed within the scope of the research. Fifty-five percent of CNVs were found to be duplication (55%) and forty-five percent were deletions (45%). As a result of the evaluation, deletion was detected in 19 (35%) of 54 genes, duplication was detected in 26 (48%), while in 3 (6%) both deletion and duplication were detected. Although CNV detected in autosomal chromosomes (chromosome 1, 2, 3, 4, 5, 7, 8, 10, 12, 13, 14, 15 and 20), CNV was established the most common in X chromosome. In our study, CNVs associated with COX7B, ZIC1, MECP2, FMR1, HOXD13, JAG1, MSX2, NEXN, and SIX3 genes were found to be more frequent in terms of fetal loss etiology.
Anahtar Kelimeler
Proje Numarası
Kaynakça
- 1. Smith GCS. Screening and prevention of stillbirth. Best Pract Res Clin Obstet Gynaecol. 2017;38:71–82.
- 2. Sahoo T, Dzidic N, Strecker MN, Commander S, Travis MK, Doherty C, et al. Comprehensive genetic analysis of pregnancy loss by chromosomal microarrays: outcomes, benefits, and challenges. Genet Med. 2017;19(1):83–9.
- 3. Harris RA, Ferrari F, Ben‐Shachar S, Wang X, Saade G, Van Den Veyver I, et al. Genome‐wide array‐based copy number profiling in human placentas from unexplained stillbirths. Prenat Diagn. 2011;31(10):932–44.
- 4. Donaghue C, Davies N, Ahn JW, Thomas H, Ogilvie CM, Mann K. Efficient and cost-effective genetic analysis of products of conception and fetal tissues using a QF-PCR/array CGH strategy; five years of data. Mol Cytogenet. 2017;10(1):12.
- 5. Massalska D, Zimowski JG, Bijok J, Pawelec M, Czubak‐Barlik M, Jakiel G, et al. First trimester pregnancy loss: clinical implications of genetic testing. J Obstet Gynaecol Res. 2017;43(1):23–9.
- 6. Raca G, Artzer A, Thorson L, Huber S, Modaff P, Laffin J, et al. Array‐based comparative genomic hybridization (aCGH) in the genetic evaluation of stillbirth. Am J Med Genet Part A. 2009;149(11):2437–43.
- 7. Rosenfeld JA, Tucker ME, Escobar LF, Neill NJ, Torchia BS, McDaniel LD, et al. Diagnostic utility of microarray testing in pregnancy loss. Ultrasound Obstet Gynecol. 2015;46(4):478–86.
- 8. Nijkamp JW, Sebire NJ, Bouman K, Korteweg FJ, Erwich J, Gordijn SJ. Perinatal death investigations: What is current practice? In: Seminars in Fetal and Neonatal Medicine. Elsevier; 2017. p. 167–75.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yazarlar
Barış Paksoy
*
0000-0002-5101-2939
Türkiye
Ozturk Ozdemır
0000-0003-1057-3235
Türkiye
Fatma Sılan
0000-0001-7191-2240
Türkiye
Yayımlanma Tarihi
31 Aralık 2020
Gönderilme Tarihi
20 Temmuz 2020
Kabul Tarihi
16 Eylül 2020
Yayımlandığı Sayı
Yıl 2020 Cilt: 17 Sayı: 4